Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2014

Open Access 01-12-2014 | Case report

Bilateral renal ischemia after kyphoplasty and clodronate treatment: a case report

Authors: Angela Notarnicola, Giuseppe Maccagnano, Alessio Casalino, Lorenzo Moretti, Andrea Piazzolla, Biagio Moretti

Published in: Journal of Medical Case Reports | Issue 1/2014

Login to get access

Abstract

Introduction

The most common adverse effects associated with bisphosphonates are renal toxicity, acute-phase reactions, gastrointestinal toxicity, osteonecrosis of the jaw, transitory fever and uveitis. We report a unique adverse case of vasculitis induced by clodronate.

Case presentation

A 61-year-old Caucasian woman developed bilateral renal ischemia after kyphoplasty and clodronate treatment for lumbar vertebral fracture. Tests revealed a vasculitis due to clodronate treatment. The antithrombotic and immunosuppressive drugs allowed us to reduce the extent of the renal ischemia. In the following months the increased auto-antibodies returned to the healthy physiological range, but the chronic renal failure persisted.

Conclusions

Drug-induced vasculitis is an inflammation of blood vessels caused by the use of various pharmaceutical agents. The spectrum of drug-induced vasculitis can range from cutaneous rashes to fatal multi-organ involvement. To the best of our knowledge this is the first documented case of drug-induced vasculitis caused by clodronate in the literature. Previously, it was verified that clodronate injection could increase the pro-apoptotic action on immune cells. Further studies are necessary to clarify the role of bisphosphonates on drug-inducing vasculitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Frediani B, Cavalieri L, Cremonesi G: Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig. 2009, 29: 359-379. 10.2165/00044011-200929060-00001.CrossRefPubMed Frediani B, Cavalieri L, Cremonesi G: Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig. 2009, 29: 359-379. 10.2165/00044011-200929060-00001.CrossRefPubMed
2.
go back to reference Ghinoi V, Brandi ML: Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother. 2002, 3: 1643-1656. 10.1517/14656566.3.11.1643.CrossRefPubMed Ghinoi V, Brandi ML: Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother. 2002, 3: 1643-1656. 10.1517/14656566.3.11.1643.CrossRefPubMed
3.
go back to reference Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002, 62: 1255-1262.CrossRef Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002, 62: 1255-1262.CrossRef
4.
go back to reference Koay MA, Gao X, Washington MK, Parman KS, Sadikot RT, Blackwell TS, Christman JW: Macrophages are necessary for maximal nuclear factor-kappa B activation in response to endotoxin. Am J Respir Cell Mol Biol. 2002, 26: 572-578. 10.1165/ajrcmb.26.5.4748.CrossRefPubMed Koay MA, Gao X, Washington MK, Parman KS, Sadikot RT, Blackwell TS, Christman JW: Macrophages are necessary for maximal nuclear factor-kappa B activation in response to endotoxin. Am J Respir Cell Mol Biol. 2002, 26: 572-578. 10.1165/ajrcmb.26.5.4748.CrossRefPubMed
5.
go back to reference Itoh F, Aoyagi S, Kusama H, Kojima M, Kogo H: Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation. 2004, 28: 15-21.CrossRefPubMed Itoh F, Aoyagi S, Kusama H, Kojima M, Kogo H: Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation. 2004, 28: 15-21.CrossRefPubMed
6.
go back to reference Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Mönkkönen J: Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999, 8: 109-118. 10.1016/S0928-0987(98)00065-7.CrossRefPubMed Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Mönkkönen J: Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999, 8: 109-118. 10.1016/S0928-0987(98)00065-7.CrossRefPubMed
7.
go back to reference Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P: An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997, 61: 386-392. 10.1007/s002239900353.CrossRefPubMed Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P: An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997, 61: 386-392. 10.1007/s002239900353.CrossRefPubMed
9.
go back to reference Warriner AH, Saag KG: Osteoporosis diagnosis and medical treatment. Orthop Clin North Am. 2013, 44: 125-135. 10.1016/j.ocl.2013.01.005.CrossRefPubMed Warriner AH, Saag KG: Osteoporosis diagnosis and medical treatment. Orthop Clin North Am. 2013, 44: 125-135. 10.1016/j.ocl.2013.01.005.CrossRefPubMed
10.
go back to reference Frediani B, Cavalieri L, Cremonesi G: Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig. 2009, 29: 359-379. 10.2165/00044011-200929060-00001.CrossRefPubMed Frediani B, Cavalieri L, Cremonesi G: Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig. 2009, 29: 359-379. 10.2165/00044011-200929060-00001.CrossRefPubMed
11.
go back to reference Rovetta G, Maggiani G, Molfetta L, Monteforte P: One-month follow-up of patients treated by intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res. 2001, 27: 77-81.PubMed Rovetta G, Maggiani G, Molfetta L, Monteforte P: One-month follow-up of patients treated by intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res. 2001, 27: 77-81.PubMed
12.
go back to reference Thomson KR, Varma K: Safe use of radiographic contrast media. Aust Prescr. 2010, 33: 19-22.CrossRef Thomson KR, Varma K: Safe use of radiographic contrast media. Aust Prescr. 2010, 33: 19-22.CrossRef
13.
go back to reference Chung SE, Lee SH, Kim TH, Yoo KH, Jo BJ: Renal cement embolism during percutaneous vertebroplasty. Eur Spine J. 2006, 15: 590-594. 10.1007/s00586-005-0037-0.CrossRefPubMed Chung SE, Lee SH, Kim TH, Yoo KH, Jo BJ: Renal cement embolism during percutaneous vertebroplasty. Eur Spine J. 2006, 15: 590-594. 10.1007/s00586-005-0037-0.CrossRefPubMed
14.
go back to reference Pitton MB, Drees P, Schneider J, Brecher B, Herber S, Mohr W, Eckardt A, Heine J, Thelen M: [Evaluation of percutaneous vertebroplasty in osteoporotic vertebral fractures using a combination of CT fluoroscopy and conventional lateral fluoroscopy]. Rofo. 2004, 176: 1005-1012. 10.1055/s-2004-813191.CrossRefPubMed Pitton MB, Drees P, Schneider J, Brecher B, Herber S, Mohr W, Eckardt A, Heine J, Thelen M: [Evaluation of percutaneous vertebroplasty in osteoporotic vertebral fractures using a combination of CT fluoroscopy and conventional lateral fluoroscopy]. Rofo. 2004, 176: 1005-1012. 10.1055/s-2004-813191.CrossRefPubMed
15.
go back to reference Cacciapaglia F, Spadaccio C, Gregorj C, Margiotta D, Coccia R, De Marco F, Chello M, Picardi A, Amoroso A, Afeltra A: Apoptosis and autoimmunity induced by clodronate in systemic lupus erythematosus mononuclear circulating cells. Int J Immunopathol Pharmacol. 2010, 23: 535-542.PubMed Cacciapaglia F, Spadaccio C, Gregorj C, Margiotta D, Coccia R, De Marco F, Chello M, Picardi A, Amoroso A, Afeltra A: Apoptosis and autoimmunity induced by clodronate in systemic lupus erythematosus mononuclear circulating cells. Int J Immunopathol Pharmacol. 2010, 23: 535-542.PubMed
16.
go back to reference Luxton G, Langham R, Caring for Australians with Renal Impairment (CARI): The CARI guidelines: ANCA serology in the diagnosis and management of ANCA-associated renal vasculitis. Nephrology. 2008, 13 (Suppl 2): S17-S23.CrossRefPubMed Luxton G, Langham R, Caring for Australians with Renal Impairment (CARI): The CARI guidelines: ANCA serology in the diagnosis and management of ANCA-associated renal vasculitis. Nephrology. 2008, 13 (Suppl 2): S17-S23.CrossRefPubMed
17.
go back to reference Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M: Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther. 2005, 7: R1072-R1081. 10.1186/ar1789.CrossRefPubMedPubMedCentral Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M: Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther. 2005, 7: R1072-R1081. 10.1186/ar1789.CrossRefPubMedPubMedCentral
18.
go back to reference Denissen NH, Peters JG, Masereeuw R, Barrera P: Can sulfasalazine therapy induce or exacerbate Wegener’s granulomatosis?. Scand J Rheumatol. 2008, 37: 72-74. 10.1080/03009740701607117.CrossRefPubMed Denissen NH, Peters JG, Masereeuw R, Barrera P: Can sulfasalazine therapy induce or exacerbate Wegener’s granulomatosis?. Scand J Rheumatol. 2008, 37: 72-74. 10.1080/03009740701607117.CrossRefPubMed
19.
go back to reference Ralston DR, Marsh CB, Lowe MP, Wewers MD: Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest. 1997, 100: 1416-1424. 10.1172/JCI119662.CrossRefPubMedPubMedCentral Ralston DR, Marsh CB, Lowe MP, Wewers MD: Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest. 1997, 100: 1416-1424. 10.1172/JCI119662.CrossRefPubMedPubMedCentral
20.
Metadata
Title
Bilateral renal ischemia after kyphoplasty and clodronate treatment: a case report
Authors
Angela Notarnicola
Giuseppe Maccagnano
Alessio Casalino
Lorenzo Moretti
Andrea Piazzolla
Biagio Moretti
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-8-76

Other articles of this Issue 1/2014

Journal of Medical Case Reports 1/2014 Go to the issue